BoFA Says Novo Nordisk May Miss Q1 Expectations as Wegovy, Ozempic Sales Lag
GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales ...
24/7 Wall St.13d
Novo Nordisk (NVO) Price Prediction and Forecast 2025-2030 (March 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Food Processing1d
European Pharma Giant Takes an Interest in Defining Ultraprocessed Foods
Novo Nordisk Foundation, ultimate parent of weight loss drugs Ozempic and Wegovy, awards a grant to University of Copenhagen ...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...
Business Insider2d
Novo Nordisk presents results from STRIDE study on Ozempic
Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1 ...
News Nation on MSN6d
Study links Wegovy to increased hair loss risk
Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in ...
Healthline5d
Ozempic: How It’s Used for Weight Loss
Ozempic (semaglutide) is a prescription drug that some doctors may prescribe off-label for weight loss. The drug isn’t approved for this use, but it may be helpful for weight loss and weight ...